Loading...
XNAS
CDXC
Market cap501mUSD
Apr 14, Last price  
6.14USD
Name

Chromadex Corp

Chart & Performance

D1W1MN
XNAS:CDXC chart
P/E
55.83
P/S
4.79
EPS
0.11
Div Yield, %
Shrs. gr., 5y
6.92%
Rev. gr., 5y
16.56%
Revenues
100m
+19.18%
04,506,3015,777,8657,566,3708,112,61011,610,49410,160,96415,313,17922,014,14026,811,08621,201,48231,557,00046,291,00059,257,00067,449,00072,050,00083,570,00099,597,000
Net income
9m
P
-38,382-2,104,476-907,568-2,051,676-7,894,984-11,662,426-4,419,525-5,388,185-2,771,067-2,928,185-11,377,618-33,316,000-31,471,000-18,483,000-25,557,000-14,449,000-4,938,0008,550,000
CFO
12m
+70.14%
-38,483-1,921,371-396,172-2,661,550-4,098,829-10,119,713-3,906,011-2,580,406-2,111,138-2,936,596-9,804,178-20,908,000-20,439,000-10,600,000-24,163,000-15,098,0007,117,00012,109,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
IPO date
Jun 25, 2007
Employees
113
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122016‑00
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT